Notice on Convening the 2024 Annual General Meeting
Filed with SSE · · 7 pages · Chinese
Chongqing Genrix Biopharmaceutical Co., Ltd. on 6ix
Earlier from Chongqing Genrix Biopharmaceutical
- Preliminary Earnings Estimate for 2024
- Announcement on the Voluntary Disclosure Regarding the Initiation of Phase III Clinical Trial for GR1802 Injection in the Indication of Chronic Spontaneous Urticaria
- Voluntary Disclosure Announcement on the Approval of Marketing Application for New Indications of Xeligekimab
- Annual Earnings Preannouncement for 2024
- Announcement on Voluntary Disclosure on the Acceptance of New Drug Application for Silevimig Injection
Later from Chongqing Genrix Biopharmaceutical
- Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing
- Announcement on Voluntary Disclosure on the Acceptance of New Drug Application for GR2001 Injection
- Announcement on Initial Public Offering of Restricted Shares under Strategic Allotment for Circulation
- Announcement on Resolutions of the 2024 Annual General Meeting
- Announcement on Progress in Repurchasing Shares
Follow Chongqing Genrix Biopharmaceutical into a list and get an email when it puts out news.
Follow Chongqing Genrix Biopharmaceutical